Celladon Gets $43M For Heart Failure Treatments

La Jolla-based Celladon Corporation, a developer of biopharmaceuticals targeting cardiovascular disease, said Wednesday afternoon that it has raised $43M in a financing round. The round was led by Pfizer Venture Investments, and also included Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners--all new investors--along with prior investors Enterprise Partners Venture Capital, Johnson & Johnson Development Corporation, and Venrock Associates. Pfizer's Barbara Dalton, Lundbeckford's Johan Kodel, Norvartis' Lauren Silverman, H&Q's Daniel Omstead, and Josh Funder of GBS have all joined the company's board as part of the financing round. Celladon is developing a compound for treating heart failure. More information »